Asthma – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Asthma – Pipeline Review, H1 2018’, provides an overview of the Asthma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Asthma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Asthma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Asthma

– The report reviews pipeline therapeutics for Asthma by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Asthma therapeutics and enlists all their major and minor projects

– The report assesses Asthma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Asthma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Asthma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Asthma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma PLC

AB Science SA

AbbVie Inc

Abeome Corp

Accolade Pharmaceuticals LLC

Adamis Pharmaceuticals Corp

ALK-Abello AS

Allergan Plc

Allergopharma GmbH & Co KG

Almirall SA

Amgen Inc

Amphastar Pharmaceuticals Inc

AnaptysBio Inc

AnGes Inc

Antisense Therapeutics Ltd

Apollo Endosurgery Inc

ARA Healthcare Pvt Ltd

ASIT Biotech SA

Aslan Pharmaceuticals Pte Ltd

Astellas Pharma Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Biotec Pharmacon ASA

Boehringer Ingelheim GmbH

Cellular Biomedicine Group Inc

Celon Pharma SA

Chiesi Farmaceutici SpA

Circassia Pharmaceuticals Plc

Cognosci Inc

Crossject SA

CrystalGenomics Inc

CSL Ltd

Cumberland Pharmaceuticals Inc

Cynata Therapeutics Ltd

Cytokinetics Inc

Daiichi Sankyo Co Ltd

Denceptor Therapeutics Ltd

Energenesis Biomedical Co Ltd

Enterprise Therapeutics Ltd

F. Hoffmann-La Roche Ltd

Fountain Biopharma Inc

Genentech Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Griffin Discoveries BV

Han Wha Pharma Co Ltd

Hydra Biosciences Inc

iCeutica Inc

iCo Therapeutics Inc.

Icure Pharmaceutical Inc

Idorsia Ltd

InKemia IUCT Group SA

Inspyr Therapeutics Inc

Intech Biopharm Ltd

Invion Ltd

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Kissei Pharmaceutical Co Ltd

Knopp Biosciences LLC

Kyowa Hakko Kirin Co Ltd

Laboratorios LETI SL

Lead Discovery Center GmbH

LG Chem Ltd

Longevity Biotech Inc

Medicenna Therapeutics Corp

MedImmune LLC

Merck & Co Inc

Mitsubishi Tanabe Pharma Corp

Mycenax Biotech Inc

NAL Pharmaceuticals Ltd

NeoPharm Co Ltd

Novartis AG

Omeros Corp

Ono Pharmaceutical Co Ltd

OPKO Health Inc

Orbis Biosciences Inc

Orchid Pharma Ltd

Orion Corporation

Oxagen Ltd

Paradigm Biopharmaceuticals Ltd

Pfizer Inc

Pharmaxis Ltd

Pieris Pharmaceuticals Inc

Polyphor Ltd

Progenra Inc

Promedior Inc

Prommune Inc

Pulmagen Therapeutics LLP

Pulmatrix Inc

Pulmokine Inc

Pulmotect Inc

Qu Biologics Inc

Qurient Co Ltd

Re-Pharm Ltd

Regeneron Pharmaceuticals Inc

Reliance Life Sciences Pvt Ltd

Respiratorius AB

ReveraGen BioPharma Inc

Saje Pharma LLC

SolAeroMed Inc

Sterna biologicals GmbH & Co KG

Sumitomo Chemical Co Ltd

Sumitomo Dainippon Pharma Co Ltd

Sun Pharmaceutical Industries Ltd

Swecure AB

Synermore Biologics Co Ltd

TaiwanJ Pharmaceuticals Co Ltd

Teva Pharmaceutical Industries Ltd

The Geneva Biotech Center SA

Therabron Therapeutics Inc

Theravance Biopharma Inc

Tolerys SA

United BioPharma Inc

Vectura Group Plc

Verona Pharma Plc

WhanIn Pharmaceutical Co Ltd

Xencor Inc

Zai Lab Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Asthma Overview 9

Asthma Therapeutics Development 10

Asthma Therapeutics Assessment 37

Asthma Companies Involved in Therapeutics Development 55

Asthma Drug Profiles 108

Asthma Dormant Projects 524

Asthma Discontinued Products 549

Asthma Product Development Milestones 555

Appendix 566

List of Tables

List of Tables

Table 1: Number of Products under Development for Asthma, H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Table 7: Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Table 8: Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Table 9: Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Table 10: Number of Products under Development by Universities/Institutes, H1 2018

Table 11: Products under Development by Companies, H1 2018

Table 12: Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 13: Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 14: Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Table 15: Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Table 16: Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Table 17: Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Table 18: Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Table 19: Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Table 20: Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Table 21: Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Table 22: Products under Development by Companies, H1 2018 (Contd..11), H1 2018

Table 23: Products under Development by Universities/Institutes, H1 2018

Table 24: Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Table 25: Number of Products by Stage and Target, H1 2018

Table 26: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Table 27: Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Table 28: Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018

Table 29: Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018

Table 30: Number of Products by Stage and Target, H1 2018 (Contd..5), H1 2018

Table 31: Number of Products by Stage and Mechanism of Action, H1 2018

Table 32: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Table 33: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018

Table 34: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018

Table 35: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018

Table 36: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018

Table 37: Number of Products by Stage and Route of Administration, H1 2018

Table 38: Number of Products by Stage and Molecule Type, H1 2018

Table 39: Asthma Pipeline by 4D Pharma PLC, H1 2018

Table 40: Asthma Pipeline by AB Science SA, H1 2018

Table 41: Asthma Pipeline by AbbVie Inc, H1 2018

Table 42: Asthma Pipeline by Abeome Corp, H1 2018

Table 43: Asthma Pipeline by Accolade Pharmaceuticals LLC, H1 2018

Table 44: Asthma Pipeline by Adamis Pharmaceuticals Corp, H1 2018

Table 45: Asthma Pipeline by ALK-Abello AS, H1 2018

Table 46: Asthma Pipeline by Allergan Plc, H1 2018

Table 47: Asthma Pipeline by Allergopharma GmbH & Co KG, H1 2018

Table 48: Asthma Pipeline by Almirall SA, H1 2018

Table 49: Asthma Pipeline by Amgen Inc, H1 2018

Table 50: Asthma Pipeline by Amphastar Pharmaceuticals Inc, H1 2018

Table 51: Asthma Pipeline by AnaptysBio Inc, H1 2018

Table 52: Asthma Pipeline by AnGes Inc, H1 2018

Table 53: Asthma Pipeline by Antisense Therapeutics Ltd, H1 2018

Table 54: Asthma Pipeline by Apollo Endosurgery Inc, H1 2018

Table 55: Asthma Pipeline by ARA Healthcare Pvt Ltd, H1 2018

Table 56: Asthma Pipeline by ASIT Biotech SA, H1 2018

Table 57: Asthma Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018

Table 58: Asthma Pipeline by Astellas Pharma Inc, H1 2018

Table 59: Asthma Pipeline by AstraZeneca Plc, H1 2018

Table 60: Asthma Pipeline by Aurigene Discovery Technologies Ltd, H1 2018

Table 61: Asthma Pipeline by Biotec Pharmacon ASA, H1 2018

Table 62: Asthma Pipeline by Boehringer Ingelheim GmbH, H1 2018

Table 63: Asthma Pipeline by Cellular Biomedicine Group Inc, H1 2018

Table 64: Asthma Pipeline by Celon Pharma SA, H1 2018

Table 65: Asthma Pipeline by Chiesi Farmaceutici SpA, H1 2018

Table 66: Asthma Pipeline by Circassia Pharmaceuticals Plc, H1 2018

Table 67: Asthma Pipeline by Cognosci Inc, H1 2018

Table 68: Asthma Pipeline by Crossject SA, H1 2018

Table 69: Asthma Pipeline by CrystalGenomics Inc, H1 2018

Table 70: Asthma Pipeline by CSL Ltd, H1 2018

List of Figures

List of Figures

Figure 1: Number of Products under Development for Asthma, H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products under Development by Universities/Institutes, H1 2018

Figure 4: Number of Products by Top 10 Targets, H1 2018

Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018

Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Figure 10: Number of Products by Top 10 Molecule Types, H1 2018

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports